The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Lung Cancer Staging

Comprehensive systematic process of determining the extent of lung cancer (location and size of primary tumor T, regional lymph node involvement N, distant metastasis M) using TNM classification system (8th edition AJCC/UICC, current standard since 2017) for non-small cell lung cancer NSCLC and modified Veterans Administration Lung Study Group (VALSG) classification for small cell lung cancer SCLC (limited stage versus extensive stage); essential for prognosis estimation, treatment planning (surgery for early-stage NSCLC, combined modalities for advanced disease, palliative care for end-stage), and clinical trial eligibility; staging modalities include high-resolution CT chest with IV contrast, PET-CT (functional imaging detecting hypermetabolic lesions, sensitivity 80-90 percent for distant metastasis), MRI brain (detecting clinically silent metastases in 5-10 percent), bone scan if clinical suspicion, endobronchial ultrasound EBUS-TBNA for mediastinal lymph node sampling (sensitivity 90 percent versus 80 percent mediastinoscopy), endoscopic ultrasound EUS for posterior mediastinum, mediastinoscopy for definitive lymph node sampling when EBUS inadequate, and rarely thoracoscopy/laparoscopy; multidisciplinary tumor board essential for staging confirmation and treatment planning.

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Göğüs Hastalıkları department. Book Appointment →

What is Lung Cancer Staging?

Lung cancer staging is the comprehensive systematic determination of the anatomic extent of the disease, essential for prognosis estimation, treatment planning, and clinical research participation. Lung cancer is the leading cause of cancer death worldwide (1.8 million deaths annually), with non-small cell lung cancer (NSCLC) representing 85 percent of cases and small cell lung cancer (SCLC) 15 percent. Accurate staging directs treatment selection — early-stage disease is potentially curable with surgery, while advanced disease requires multimodal treatment with chemotherapy, radiation, immunotherapy, and targeted therapies, and end-stage disease focuses on palliative care.

TNM staging system (8th edition AJCC/UICC, effective 2017): primary parameters: 1) T descriptor (primary tumor) — T0 (no evidence of primary tumor), Tis (carcinoma in situ), T1a (≤1 cm), T1b (>1-2 cm), T1c (>2-3 cm), T2a (>3-4 cm or main bronchus involvement 2 cm or more distal to carina, visceral pleural invasion, atelectasis), T2b (>4-5 cm with same features), T3 (>5-7 cm or invasion of chest wall, parietal pleura, phrenic nerve, parietal pericardium, separate tumor nodule in same lobe), T4 (>7 cm or invasion of mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, carina, separate tumor nodule in different ipsilateral lobe); 2) N descriptor (regional lymph node involvement) — N0 (no regional nodal involvement), N1 (ipsilateral peribronchial nodes, ipsilateral hilar lymph nodes — stations 10-14), N2 (ipsilateral mediastinal lymph nodes, subcarinal nodes — stations 1-9), N3 (contralateral mediastinal or hilar nodes, any supraclavicular nodes, scalene); 3) M descriptor (distant metastasis) — M0 (no distant metastasis), M1a (separate tumor nodule in contralateral lobe, pleural nodules, pericardial nodules, malignant pleural or pericardial effusion), M1b (single extrathoracic metastasis), M1c (multiple extrathoracic metastases in single or multiple organs); stage groupings combine T, N, M values: IA1 (T1aN0M0), IA2 (T1bN0M0), IA3 (T1cN0M0), IB (T2aN0M0), IIA (T2bN0M0), IIB (T1-2N1M0 or T3N0M0), IIIA (T1-2N2M0, T3N1M0, T4N0-1M0), IIIB (T1-2N3M0, T3-4N2M0), IIIC (T3-4N3M0), IVA (T any N any M1a or M1b — single distant metastasis), IVB (T any N any M1c — multiple distant metastases).

SCLC staging — modified Veterans Administration Lung Study Group (VALSG): two-stage system simpler than NSCLC: 1) Limited stage (LS-SCLC) — confined to ipsilateral hemithorax with all involved sites able to be encompassed in single radiation port; includes mediastinal nodes (ipsilateral and contralateral), supraclavicular nodes, and ipsilateral hilar nodes; treatment with concurrent chemoradiation has 5-year survival 30 percent; 2) Extensive stage (ES-SCLC) — disease beyond ipsilateral hemithorax including malignant pleural effusion, contralateral hilar nodes, distant metastasis; treatment focuses on chemotherapy with possible immunotherapy, 5-year survival 5-10 percent; SCLC has been increasingly being staged using TNM as well for clinical and research purposes.

Staging modalities: 1) High-resolution CT chest with intravenous contrast — initial staging for primary tumor, regional lymph nodes, mediastinum, pleural disease; size measurements, invasion assessment; 2) PET-CT (positron emission tomography combined with CT) — functional imaging using fluorodeoxyglucose (FDG) detecting hypermetabolic lesions; sensitivity 80-90 percent for distant metastasis (false negatives in small lesions, well-differentiated adenocarcinoma, brain metastasis); evaluates mediastinal lymph nodes, distant metastases including liver, adrenal, skeletal, soft tissue; reduces unnecessary thoracotomy by detecting unsuspected metastasis in 15 percent; 3) MRI brain — detects clinically silent brain metastasis in 5-10 percent of asymptomatic NSCLC; recommended for all stage III and IV NSCLC, all SCLC, and selected stage I-II with neurologic symptoms; 4) Bone scan — typically replaced by PET-CT when available; reserved for clinical bone pain or symptoms; 5) Endobronchial ultrasound (EBUS)-TBNA — convex probe EBUS allows real-time ultrasound-guided needle aspiration of mediastinal and parabronchial lymph nodes; sensitivity 90 percent and specificity 100 percent for malignant lymph nodes; advantages over mediastinoscopy include outpatient procedure, lower morbidity, can sample stations not reachable by mediastinoscopy (4L in addition to 4R, 7); 6) Endoscopic ultrasound (EUS) — useful for posterior mediastinal nodes (stations 8-9) and assessment of esophageal invasion; complementary to EBUS; 7) Mediastinoscopy — definitive sampling of mediastinal nodes when EBUS-TBNA inadequate or unavailable; particularly important for confirmed N2 disease before resection consideration; 8) Thoracoscopy/VATS — for pleural disease evaluation, rarely needed; 9) Tissue diagnosis — biopsy of suspicious lesions for molecular testing (EGFR, ALK, ROS1, KRAS, BRAF mutations, PD-L1 expression) which determines targeted therapy and immunotherapy eligibility.

Symptoms

Confirmed lung cancer diagnosis requiring staging
Persistent cough with mass on imaging
Hemoptysis with new lung lesion
Chest pain with abnormal CT findings
Weight loss with lung cancer suspicion
Fatigue with imaging findings
Solitary pulmonary nodule requiring biopsy
Mediastinal lymphadenopathy
Suspicious imaging requiring tissue diagnosis
Bone pain with primary lung mass (rule out metastasis)
Neurologic symptoms (headache, focal deficits — brain metastasis)
Adrenal mass with lung cancer (rule out metastasis)
Liver lesion with lung cancer (rule out metastasis)
Supraclavicular lymph node enlargement (Virchow node)
Symptoms of superior vena cava obstruction
Hoarseness with hilar mass (recurrent laryngeal nerve invasion)
Phrenic nerve palsy with mass
Horner syndrome (Pancoast tumor)
Pleural effusion with new lung mass
Pericardial effusion with lung mass
Multiple pulmonary nodules requiring evaluation
Pre-treatment evaluation
Clinical trial enrollment requirements

Risk Factors

Smoking (most important risk factor — 85 percent of lung cancer cases)
Cumulative tobacco exposure (pack-years)
Secondhand smoke exposure
Radon gas exposure (geographic risk)
Asbestos exposure (mesothelioma risk additional)
Other occupational carcinogens (chromium, nickel, polycyclic aromatic hydrocarbons, diesel exhaust)
Family history of lung cancer (3-fold increased risk)
Prior chest radiation
Pulmonary fibrosis
Chronic obstructive pulmonary disease
HIV infection (increased risk)
Tuberculosis history
Heavy alcohol use
Diet low in fruits and vegetables
Air pollution exposure
Older age (median age at diagnosis 70)
Male sex (slightly higher overall risk, female biased lung cancer in non-smokers)
African American race (slightly higher risk)
Genetic predisposition (rare familial syndromes — Li-Fraumeni, hereditary lung cancer with EGFR T790M germline)
Indoor air pollution (biomass fuels, cooking smoke)

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • Lung cancer diagnosis confirmed — staging needed
  • New abnormal chest X-ray or CT requiring evaluation
  • Suspicious pulmonary nodule on screening CT (LDCT)
  • Persistent unexplained cough lasting > 6 weeks
  • Hemoptysis (any amount)
  • Unexplained weight loss with respiratory symptoms
  • Chest pain in smoker
  • Recurrent pneumonia in same lobe
  • Persistent atelectasis on imaging
  • Mediastinal lymphadenopathy
  • Suspicion of metastasis
  • Pre-treatment planning evaluation
  • Clinical trial consideration
  • Treatment progression evaluation
  • Restaging after initial treatment
  • Recurrence surveillance
  • New symptoms during follow-up
  • Disease progression monitoring
  • Multidisciplinary tumor board evaluation
  • Second opinion for treatment decisions

Treatment Methods

01
Initial assessment for staging: 1) Confirmed pathologic diagnosis of lung cancer (small biopsy or fine-needle aspiration) with molecular testing for NSCLC (EGFR, ALK, ROS1, KRAS, BRAF, NTRK, RET, MET, HER2 mutations; PD-L1 expression for immunotherapy candidate assessment); 2) Comprehensive history including smoking history, occupational exposures, prior cancer history, family history, comorbidities, performance status assessment (ECOG, Karnofsky); 3) Physical examination — lymph node assessment (cervical, supraclavicular, axillary), chest examination, neurologic assessment, abdominal examination for hepatomegaly; 4) Performance status — ECOG 0 (asymptomatic), 1 (symptomatic but ambulatory), 2 (in bed < 50 percent), 3 (in bed > 50 percent), 4 (bedridden); important for treatment decisions
02
Imaging studies for staging: 1) High-resolution CT chest with IV contrast — comprehensive evaluation of primary tumor (size, location, invasion of structures), regional lymph nodes (size > 1 cm short axis suspicious), mediastinum, pleural disease, distant abdominal organs (liver, adrenals); 2) PET-CT (FDG-PET combined with CT) — recommended for all clinical stage IB and higher NSCLC for confirmation of staging and detection of distant metastasis; sensitivity 80-90 percent, specificity 80-90 percent; particularly valuable for ruling out distant metastasis and identifying suspicious mediastinal nodes; 3) MRI brain with contrast — recommended for stage III and IV NSCLC and all SCLC, also for stage I-II with neurologic symptoms or signs; detects clinically silent brain metastasis in 5-10 percent; 4) Bone scan — typically replaced by PET-CT, reserved for clinical bone pain when PET-CT unavailable; 5) Adrenal MRI or biopsy — for adrenal mass evaluation when CT/PET-CT inconclusive (10-15 percent of patients have adrenal lesions, half are benign adenomas)
03
Tissue sampling for staging: 1) Endobronchial ultrasound (EBUS)-TBNA — first-line for mediastinal lymph node sampling; sensitivity 90 percent and specificity 100 percent for malignant lymph nodes; outpatient procedure under conscious sedation, samples stations 2R, 2L, 4R, 4L, 7, 10, 11, 12; 2) Endoscopic ultrasound (EUS) — for posterior mediastinum nodes (stations 8, 9) and esophageal evaluation; can be combined with EBUS for comprehensive staging; 3) Mediastinoscopy — definitive surgical sampling of mediastinal nodes; cervical mediastinoscopy for stations 2, 4, 7; anterior mediastinotomy (Chamberlain procedure) for stations 5, 6; less common with widespread EBUS-TBNA availability but still valuable when EBUS inadequate; 4) Thoracoscopy/VATS — for pleural disease evaluation and rare cases needing pleural staging; 5) CT-guided biopsy — for peripheral lung lesions when bronchoscopy unable to reach
04
Stage assignment using TNM: 1) Apply 8th edition criteria systematically; 2) Best classification represents both clinical staging (cTNM, based on imaging and minimally invasive tissue sampling) and pathologic staging (pTNM, after surgical resection — definitive); 3) Stage groupings (IA1-IVB) determine treatment approach; 4) Documentation in standardized format for tumor board, clinical trials, registry, and treatment planning; 5) Restaging may be needed after neoadjuvant therapy (yp prefix for post-treatment pathologic stage)
05
Multidisciplinary tumor board: 1) Essential for confirmed staging and treatment planning; 2) Members include thoracic surgeon, medical oncologist, radiation oncologist, pulmonologist, interventional pulmonologist, pathologist, radiologist, molecular pathologist, clinical research coordinators; 3) Discussion includes complete staging review, biopsy results, molecular testing results, performance status, comorbidities, patient preferences; 4) Treatment plan recommendation; 5) Clinical trial eligibility assessment; 6) Documentation and communication with primary care and patient
06
Treatment by stage NSCLC: 1) Stage IA1-IA3 (T1N0M0) — surgical resection (lobectomy preferred, sublobar resection for poor surgical candidates) with mediastinal lymph node sampling; 5-year survival 75-90 percent; 2) Stage IB (T2aN0M0) — surgical resection with mediastinal lymph node dissection; adjuvant chemotherapy (cisplatin-based doublet) for selected patients with high-risk features (large size, positive margins, vascular invasion); 5-year survival 75-80 percent; 3) Stage IIA-IIB — surgical resection with mediastinal lymph node dissection followed by adjuvant chemotherapy; consideration of induction chemotherapy for some; 5-year survival 50-65 percent; 4) Stage IIIA — multimodal treatment including induction or adjuvant chemoradiation, surgical resection in selected cases (especially T3N1, single station N2); 5-year survival 30-45 percent; 5) Stage IIIB-IIIC — concurrent chemoradiation (chemotherapy plus thoracic radiation) followed by consolidation immunotherapy (durvalumab) — PACIFIC trial showed survival benefit; 5-year survival 25-30 percent; 6) Stage IVA-IVB — systemic therapy individualized based on molecular profile and PD-L1 expression: a) EGFR/ALK/ROS1/RET/NTRK/MET/HER2/BRAF mutations — targeted therapy with tyrosine kinase inhibitors (osimertinib for EGFR, alectinib for ALK, etc.); b) High PD-L1 (>50 percent) — immunotherapy (pembrolizumab) monotherapy or combination; c) Otherwise — chemoimmunotherapy combinations (chemotherapy plus pembrolizumab); 5-year survival 5-15 percent; 7) Oligometastatic disease (1-3 metastases) — local consolidation with surgery or stereotactic radiation may extend survival
07
Treatment by stage SCLC: 1) Limited stage SCLC — concurrent chemoradiation with cisplatin-etoposide and thoracic radiation, followed by prophylactic cranial irradiation (PCI) for treatment responders to reduce brain metastasis (controversial in elderly with cognitive concerns); some trials integrating immunotherapy; 5-year survival 25-30 percent; 2) Extensive stage SCLC — chemoimmunotherapy (cisplatin/carboplatin + etoposide + atezolizumab or durvalumab) for first-line treatment; consolidation thoracic radiation in selected patients; PCI no longer routinely recommended; second-line topotecan, lurbinectedin, immunotherapy; median survival 12-13 months
08
Restaging and follow-up: 1) Restaging after neoadjuvant therapy with imaging (CT, possibly PET-CT) and tissue sampling if indicated; 2) Surveillance after curative treatment includes CT chest at 3-6 month intervals for first 2 years, then 6-12 month intervals; LDCT may replace contrast CT in stable patients; 3) Brain MRI for stage III patients (and post-stereotactic radiation); 4) PET-CT for treatment response assessment in advanced disease; 5) Symptom-directed evaluation; 6) Long-term smoking cessation support; 7) Pulmonary function monitoring; 8) Quality of life assessment; 9) Survivorship care including secondary cancer surveillance; 10) Recurrence — restaging and treatment options
09
Special considerations: 1) Pancoast tumor (superior sulcus tumor) — staged separately, multimodal treatment with chemoradiation followed by surgical resection; 2) Synchronous primary lung cancers (multifocal disease) — careful staging with separate evaluation of each lesion, may benefit from definitive treatment of each; 3) Multiple pulmonary nodules — evaluation of each nodule for primary versus metastasis; 4) Persistent or recurrent disease — repeat staging; 5) Minimal residual disease assessment with circulating tumor DNA (emerging); 6) Patient with poor performance status — modified staging approach with focus on palliative options; 7) Elderly patients — comorbidity-adjusted staging and treatment; 8) Cancer of unknown primary versus lung primary — molecular profiling; 9) Second primary lung cancer in survivor
10
Long-term outcomes and considerations: 1) Stage at diagnosis is the most important prognostic factor — early-stage NSCLC has 90+ percent 5-year survival, advanced disease 5-15 percent; 2) Continued advances in treatment with immunotherapy and targeted therapy improving survival in advanced disease (median survival has increased from 12 months to 24-30+ months in stage IV); 3) Lung cancer screening with low-dose CT in eligible patients can detect early-stage disease (USPSTF recommends LDCT screening ages 50-80 with 20+ pack-year smoking history); 4) Smoking cessation improves outcomes at any stage; 5) Survivorship care and second cancer surveillance important; 6) Clinical trial participation should always be considered; 7) Multidisciplinary management with experienced team optimizes outcomes; 8) Quality of life and palliative care integration throughout disease course; 9) Integration of cancer genomics and personalized medicine; 10) Continued research into novel therapies, combinations, and biomarkers

Which Department to Visit?

You can visit our Göğüs Hastalıkları department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Göğüs Hastalıkları Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Asthma

Göğüs Hastalıkları

Asthma is characterized by wheezing, coughing and shortness of breath attacks; with proper treatment it can be kept under control.

COPD (Chronic Obstructive Pulmonary Disease)

Göğüs Hastalıkları

COPD is an irreversible lung disease characterized by shortness of breath and chronic cough; quitting smoking slows its progression.

Pneumonia

Göğüs Hastalıkları

Pneumonia presents with high fever, cough and shortness of breath; the vast majority recover with appropriate antibiotic treatment.

Tuberculosis (TB)

Göğüs Hastalıkları

Tuberculosis presents with weeks-to-months of cough, fever, and night sweats; early diagnosis and treatment lead to full recovery.

Pleural Effusion

Göğüs Hastalıkları

Pleural effusion is the accumulation of excess fluid in the pleural space, resulting from imbalances in fluid production and removal, and represents a manifestation of diverse cardiopulmonary, infectious, and malignant disorders.

Pneumothorax

Göğüs Hastalıkları

Pneumothorax is the presence of air in the pleural space resulting in partial or complete lung collapse, classified as spontaneous (primary/secondary), traumatic, or iatrogenic, with tension pneumothorax representing a life-threatening emergency.

Bronchitis (Acute and Chronic)

Göğüs Hastalıkları

Acute bronchitis is mostly viral and resolves spontaneously, while chronic bronchitis is a smoking-related component of COPD.

Bronchiectasis

Göğüs Hastalıkları

Bronchiectasis is a chronic respiratory disease characterized by permanent, abnormal dilation of bronchi with associated destruction of muscular and elastic components of airway walls, resulting in impaired mucociliary clearance and recurrent infection.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.